Compare Globus Medical Inc. Class A Common Stock (GMED) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Intuit Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Intuit Inc. trades at $309.58 (market cap $80.56B). The key difference: Intuit Inc. is far larger — about 7.9× Globus Medical Inc. Class A Common Stock's market cap, and Intuit Inc. pays a 1.83% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Intuit Inc. for 67 Days on average.
| GMED | INTU | |
|---|---|---|
Market Cap | $10.25B | $80.56B |
Volume | 1,108,124 | 3,646,799 |
Sector | Health | Technology |
52-Week High | $96.82 | $683.39 |
52-Week Low | $58.33 | $255.07 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $9.76B | $81.78B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Intuit (INTU) trades at $305.99, up 1.07% with strong earnings momentum after beating Q4 2025 and Q1-Q2 2026 EPS estimates. The stock shows bullish technical signals with support at $302 and resistance at $312. Fundamentally, revenue grew to $18.83B in 2025 with a robust 21.29% net margin, while valuation ratios like P/E of 18.31 appear reasonable. Recent news highlights growth in QuickBooks monetization and AI initiatives, though class action lawsuits create near-term uncertainty.
Outlook remains positive with analyst consensus target of $379.68 (24% upside) and 60% buy ratings. Key opportunities include sustained revenue growth and margin expansion, while risks involve legal overhangs and competitive pressures in financial software. The stock offers attractive fundamentals but requires monitoring of lawsuit developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
